These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6388068)

  • 1. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes.
    Gratama JW; Jansen J; Lipovich RA; Tanke HJ; Goldstein G; Zwaan FE
    Transplantation; 1984 Nov; 38(5):469-74. PubMed ID: 6388068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation.
    Filipovich AH; Krawczak CL; Kersey JH; McGlave P; Ramsay NK; Goldman A; Goldstein G
    Br J Haematol; 1985 May; 60(1):143-52. PubMed ID: 3890926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
    Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
    Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent acute graft-versus-host disease. A pilot study in ten patients.
    Herve P; Flesch M; Cahn JY; Racadot E; Plouvier E; Lamy B; Rozenbaum A; Noir A; Des Floris RL; Peters A
    Transplantation; 1985 Feb; 39(2):138-43. PubMed ID: 3881852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease.
    Remlinger K; Martin PJ; Hansen JA; Doney KC; Smith A; Deeg HJ; Sullivan K; Storb R; Thomas ED
    Hum Immunol; 1984 Jan; 9(1):21-35. PubMed ID: 6198309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia.
    Prentice HG; Blacklock HA; Janossy G; Bradstock KF; Skeggs D; Goldstein G; Hoffbrand AV
    Lancet; 1982 Mar; 1(8274):700-3. PubMed ID: 6122004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase-I/II trial.
    Beelen DW; Graeven U; Schulz G; Grosse-Wilde H; Doxiadis I; Schaefer UW; Quabeck K; Sayer H; Schmidt CG
    Onkologie; 1988 Feb; 11(1):56-8. PubMed ID: 3283628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study.
    Filipovich AH; McGlave P; Ramsay NK; Goldstein G; Kersey JH
    J Clin Immunol; 1982 Jul; 2(3 Suppl):154S-157S. PubMed ID: 6752174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha.
    Gleixner B; Kolb HJ; Holler E; Liesenfeld S; Riedner C; Hiller E; Seeber C; Kempeni J; Möller A; Knabe H
    Bone Marrow Transplant; 1991 Aug; 8(2):93-8. PubMed ID: 1933064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
    Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody.
    Anasetti C; Martin PJ; Storb R; Appelbaum FR; Beatty PG; Davis J; Doney K; Hill HF; Stewart P; Sullivan KM
    Transplantation; 1992 Nov; 54(5):844-51. PubMed ID: 1440852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation.
    Filipovich AH; McGlave PB; Ramsay NK; Goldstein G; Warkentin PI; Kesey JH
    Lancet; 1982 Jun; 1(8284):1266-9. PubMed ID: 6123018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia.
    Aversa F; Terenzi A; Carotti A; Felicini R; Jacucci R; Zei T; Latini P; Aristei C; Santucci A; Martelli MP; Cunningham I; Reisner Y; Martelli MF
    J Clin Oncol; 1999 May; 17(5):1545-50. PubMed ID: 10334542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OKT3 incubation of donor marrow for prophylaxis of acute graft-vs.-host disease (GvHD) in allogeneic bone marrow transplantation.
    Prentice HG
    J Clin Immunol; 1982 Jul; 2(3 Suppl):148S-153S. PubMed ID: 6290527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin.
    Kernan NA; Byers V; Scannon PJ; Mischak RP; Brochstein J; Flomenberg N; Dupont B; O'Reilly RJ
    JAMA; 1988 Jun; 259(21):3154-7. PubMed ID: 3285046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies.
    Ringdén O; Remberger M; Carlens S; Hagglund H; Mattsson J; Aschan J; Lönnqvist B; Klaesson S; Winiarski J; Dalianis T; Olerup O; Sparrelid E; Elmhorn-Rosenborg A; Svahn BM; Ljungman P
    Transplantation; 1998 Sep; 66(5):620-5. PubMed ID: 9753343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.
    Jaffers GJ; Fuller TC; Cosimi AB; Russell PS; Winn HJ; Colvin RB
    Transplantation; 1986 May; 41(5):572-8. PubMed ID: 3085297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.